Neuropraxis Muenchen Sued

The site is conducting studies on preventive treatment for chronic and episodic migraine. One trial evaluates the safety of atogepant. Another arm assesses the tolerability of topiramate as a comparator.

• Safety and tolerability assessment
• Oral preventive therapy evaluation
• Adverse event monitoring
• Impact on migraine frequency

Neuropraxis Muenchen Sued is dedicated to advancing preventive options for patients living with migraine.

Research at the site focuses on relapsing-remitting multiple sclerosis. A study examines the pharmacokinetic profile of the biosimilar candidate ABP 692. It also compares pharmacodynamic effects with the reference product ocrelizumab.

• Pharmacokinetic similarity study
• Pharmacodynamic lesion suppression analysis
• Biosimilar safety comparison
• Potential for broader treatment access

The work at Neuropraxis Muenchen Sued supports development of more affordable therapies for MS patients.